Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). We hypothesized that empaglifozin (EMPA) co...

Source: Cardiovascular Diabetology - March 1, 2021 Category: Cardiology Authors: B. Gaborit, P. Ancel, A. E. Abdullah, F. Maurice, I. Abdesselam, A. Calen, A. Soghomonian, M. Houssays, I. Varlet, M. Eisinger, A. Lasbleiz, F. Peiretti, C. E. Bornet, Y. Lefur, L. Pini, S. Rapacchi & hellip; Tags: Original investigation Source Type: research